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Amyotrophic lateral sclerosis is a neurodegenerative disease that leads to motor weakness.
There is no cure, and treatment focuses on slowing down progression, which is achieved by
a multidisciplinary approach. Hence, it is vital to understand the population needs for an opti-
mal management of the disease.
Objectives
To evaluate the current status of amyotrophic lateral sclerosis in the region of Catalonia,
how the disease is managed and its direct medical costs.
Methods
Records corresponding to 841 patients diagnosed between the year 2007 and 2017 were
analysed in a retrospective population-based study, including data from primary care cen-
tres, hospitals (inpatient and outpatient care), extended care facilities and mental health
centres.
Results
Mean diagnosis age was 66.11 years (SD = 12.61) and 52.79% of admitted patients were
males. On average, 14.91 months elapsed between diagnosis and death, and the mean age
of death was 72.64 years (SD = 12.00). Patients were admitted 10.70 times per year, mostly
into primary care (86.50%), although most expenses were concentrated in hospital inpatient
care. The mean cost per patient per year was €1,168. The 83.24% of patients had more
than 4 systems affected by chronic conditions.
Conclusions
Primary care is of utmost importance in ALS attention in Catalonia, which may have a direct
impact in reducing hospitalisation costs. Nonetheless, the expenses linked to inpatient care
represent the biggest portion of total costs. Patients’ healthcare usage patterns and the high
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proportion of patients with multiple chronic conditions should be taken into account in order
to adapt and improve guidelines and healthcare systems.
Introduction
Amyotrophic lateral sclerosis (ALS), also known as motor neurone disease, is a neurodegener-
ative disease characterised by the degeneration of both lower and upper motor neurons leading
to motor weakness that progressively affects patients’ capacity to speak, swallow and breathe
[1]. ALS cause is genetic in 10% of cases; in most cases, its etiology remains unknown [2]. Dis-
tinct clinical phenotypes have been documented pointing to distinct pathogenic mechanisms
[3]. Thus, diagnosis can be challenging and diagnostic delays are not rare. Current estimations
situate ALS incidence in Europe at 2.3 per 100,000 males per year and 1.3 per 100,000 women
[4]. In Spain, studies based on hospitalisation registries estimate a minimum prevalence of 2
per 100,000 inhabitants [5]. Currently, there is no cure for ALS, and treatment is mostly
focused on slowing progression in an effort to improve patients’ life quality. With this aim, a
multidisciplinary approach is usually performed, reducing the number of hospitalisations [6,
7]. Hence, an optimal management of the disease should address the aforementioned issues
focusing on the population needs.
The evaluation of patient demographics has been proven to be useful in determining the
specific needs of patients and physicians regarding the use of healthcare resources, to adapt
disease management to disease complexity [8]. To facilitate such evaluations, detailed informa-
tion on healthcare usage is collected and analysed. In Catalonia, the program for data analysis
for research and innovation in health (Programa d’analı́tica de dades per a la recerca i la inno-
vació en salut, PADRIS) has been developed. This is a specialised linkage program aimed to
connect various administrative records from the same patient. PADRIS represents a useful
tool for the examination of disease management in order to develop new protocols that reflect
the disease complexity within the population [9].
In this context, the objective of this study was to revise the situation of ALS in Catalonia,
focusing on patients’ characteristics, disease management and direct medical cost in terms of
use of healthcare resources between the years 2007 and 2017.
Methods
Records of all patients diagnosed with ALS in the region of Catalonia (7.5 million inhabitants)
between 2007 and 2017 were extracted from PADRIS via ethics committee approval. Parame-
ters such as health centres and medical history identifiers were re-coded prior to extraction to
maintain records anonymised, with no access to identifying information, in accordance with
the principles of Good Clinical Practice and the Declaration of Helsinki. The data obtained
included detailed information of patients’ use of healthcare resources, comprising 429 primary
care centres, 69 hospitals (inpatient and outpatient care), 76 emergency care units (ER), 167
extended care facilities and 5 mental health centres. In all facilities, admission registry included
both inpatient and outpatient consultations. Patients’ decease was ascertained using insurance
registries (public and private), and was only available between the years 2010 and 2017. ALS
patients were ascertained using the 9th revision of the International Statistical Classification of
Diseases and Related Health Problems (ICD-9) 335.20 code. Data was provided separately and
not all databases contained data for the period of study in its totality; yet, the Health Evaluation
and Quality Agency of Catalonia assures data consistency and reliability.
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Abbreviations: ALS, Amyotrophic Lateral
Sclerosis; ER, Emergency Room; GMA, Adjusted
Morbidity Groups; ICD9, 9th revision of the
International Statistical Classification of Diseases
and Related Health Problems; ICS, Catalan Institute
of health (Institut Català de la Salut); PADRIS,
Program of data analysis for research and
innovation in health (Programa d’Analı́tica de
Dades per a la Recerca i la Innovació en Salut).
When necessary, the extraction of single-patient information was carried out conserving
the first admission of each patient to extract population descriptive statistics.
Direct medical costs associated with the use of healthcare resources were calculated based
on the mean cost of admissions and medical procedures determined by the Catalan govern-
ment for the year 2013 [9, 10]. These figures include all expenses related to the admission:
treatment (examination, medication and palliative/surgical care), nutrition, costs associated to
personnel, medical equipment and resources. This project was approved by the University of
Barcelona’s Bioethics Commission.
Subsequently, patient classification into adjusted morbidity groups (GMA), done automati-
cally according to patients’ chronic diseases and into 5 levels of complexity or risk based on
data from the year 2016, was used as additive information to disease cost. The Catalan Institute
of Health correlates GMA level with a higher number of healthcare admissions of these
patients and major medical costs, and risk level 5 corresponds to the 1% of the total population
with the highest hospitalisation risk [11]. This correlation provided qualitative complementary
data on ALS medical costs.
Data presentation is mainly descriptive. Statistical analyses were performed using Microsoft
Excel© Professional Plus 2010 (Microsoft Corporation, Redmond, WA, USA).
Results
Patient characteristics
A total of 841 patients diagnosed with ALS between the years 2007 and 2017 were recorded in
the database; 444 (52.79%) of the patients were males, 384 (45.66%) were females and in 13
(1.55%) of the files sex information was missing. Patients’ age at the time of diagnosis was
66.11 ± 12.61 years.
Given the disease characteristics, an analysis of patients deceased during the study period
was considered of interest. 716 patients with ALS died in this time period, which equals 89.5
patients per year (Table 1). The mean age at death was 72.64 ± 12.00 years. On average,
14.91 ± 1.42 months elapsed between diagnosis and death.
Disease management and costs
The aforementioned record files corresponding to the studied population registered 58,775
admissions between 2007 and 2017 in the distinct healthcare centres (primary care, hospitals,
ER, extended care facilities and mental healthcare centres) (Fig 1). The 86.50% of all admis-
sions were registered into primary care centres. These centres received on average 10.70
annual consultations per patient. Mean hospitalisation time was 5.63 ± 7.33 days, while time
Table 1. Patients with amyotrophic lateral sclerosis deceased during the study period (2007–2017). CI: confidence
interval.
Number of deceased patients 716
male patients 50.28%
female patients 44.55%
Deceased per year 89.5 patients
Patients’ age (years)
Mean ± SD 72.64 ± 12.00
Time elapsed (months)
Mean ± 95% CI 14.91 ± 1.42
Median 9
https://doi.org/10.1371/journal.pone.0223772.t001
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on extended care facilities was on average 107 days, with the median at 18 days. Admissions
into ER lasted on average less than a day, with a median of 0 days.
Admissions were classified according to their urgency, with similar proportions of sched-
uled and urgent consultations in both primary care centres and hospitals (Table 2). All admis-
sions into extended care facilities were considered scheduled. When specified, ER admissions
received a high number of patients having minor emergencies or in urgent situations with no
vital risk associated. After discharge, most patients moved to their residences, or when dis-
charged from ER, presumably at advanced stages of the disease, 28.71% of patients were trans-
ferred to extended care facilities or nursing homes (Table 3). In general terms, data suggested
that patient’s death does not occur during hospitalisation events, and only 33.81% of the
patients in extended care facilities died during the admission.
Patients with ALS displayed a variety of disease comorbidities. Secondary diagnoses regis-
tered in more than 1% of admissions were: hypertension, registered in 3.59% of admissions at
some point in patients’ disease course; breathing abnormalities (Including unspecified breath
difficulties, distress and insufficiency) registered in 1.41% of admissions; type II diabetes
appeared in 1.22% of admissions; acute bronchitis in the 1.15% and disorders of lipoid metab-
olism, hyperlipidaemia and hypercholesterolemia in the 1.16%, 1.11% and 1.04% respectively.
Fig 1. A) Distribution of admissions in the distinct healthcare centres. B) Number of admissions per patient per year.
https://doi.org/10.1371/journal.pone.0223772.g001
Table 2. Percentage of patients admitted for scheduled and urgent situations related to ALS in hospitals, ER and
primary care.
Origin of admissions Hospitals ER Primary care
Scheduled 48.11% - 46.01%
Non-scheduled/Urgent 51.89% - 53,99%
Non-urgent situations - 5.35% -
Minor emergencies - 15.23% -
Urgent situations, no vital risk - 27.14% -
Very urgent situations, vital risk - 5.81% -
Immediate vital risk - 0.23% -
Unspecified - 46.23% -
https://doi.org/10.1371/journal.pone.0223772.t002
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Most common procedures were: related to facilitating respiration (12%) with measures like
mechanical ventilation or oxygen enrichment; imaging techniques (11.32%), including mag-
netic resonance imaging of the brain and the spinal cord, computed tomography scan of head
and abdomen, thorax radiography and thorax tomography. Gastrostomies were performed in
6.34% of the cases, and electromyographies in the 3.05%. Primary care consultations were
mainly to receive intramuscular medication, blood test or sanitary education including infor-
mation on the disease course and managing of the medication.
Regarding patients’ complexity level and medical costs of the disease, the year 2016 83.24%
of patients with ALS had 4 or more systems affected by a chronic condition, 24% more than in
2014 (Fig 2A). In 2016, 26% of patients with ALS were labelled as at a very high risk, and there
were almost two times more patients displaying a certain level of risk compared to the general
population (Fig 2B and 2C).
On the other hand, the direct cost measurement associated to the use of healthcare
resources determined that €7,919,630 were destined to attend patients with ALS between 2007
and 2017 (Table 4). Data was however incomplete due to the characteristics of the database.
Taking into account all factors, the cost per year was estimated to be €981,978 with a cost per
patient per year of €1,168.
Finally, records showed that 88.94% of the patients contributed to only 10% of their phar-
maceutical expenses, which were mostly covered by the healthcare system.
Discussion
Patient characteristics
The analysis of records of ALS diagnosed patients in Catalonia allowed the assessment of ALS
current status in the region, including the evaluation of patient demographics and disease
management. In total, 841 patients were included in the study; all diagnosed with ALS between
the years 2007 and 2017. Mean age of diagnosis was consistent with previous findings in the
north of Spain and worldwide [12, 13]. Generally, incidence rates increase with age, peaking
between 65 and 74 and decline after [4].
Regarding disease duration, time elapsed between onset and decease was established at
14.91 months (1.22 years), which is comparable to previous estimations of survival averaging
20 to 48 months; while longer survivals have been measured in patients with early onsets [14].
Disease management and costs
The Spanish healthcare system, as many others, promotes the use of primary care as a way to
maximise healthcare resources [15]. Primary care centres received 86.50% of registered admis-
sions, with similar proportions of scheduled and urgent consultations. Each patient underwent
an average of 10.70 consultations each year. ALS management should ensure multidisciplinary
care, considering the wide variety of symptoms that impact patients’ life quality [7, 16].
Table 3. Percentage of patients discharged, transferred or deceased in hospitals, ER and extended care facilities.
Destination after discharge Hospitals ER Extended care
Patients’ residence 82.14% 49.49% 36.55%
Admission for inpatient care 1.17% 16.75% -
Discharge, external care 4.17% - 9.34%
Transfer to a extended care facility 3.20% 28.71% 16.24%
Death during admission 8.11% 1.84% 33.81%
Others 1.21% 3.21% 4.06%
https://doi.org/10.1371/journal.pone.0223772.t003
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Fig 2. A) Multimorbidities in patients with amyotrophic lateral sclerosis (ALS). Disease complexity levels associated to risk (1 -green- low risk to 5 -red- very high risk) in
B) general population [9] and C) patients with ALS in 2016.
https://doi.org/10.1371/journal.pone.0223772.g002
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Current treatment guidelines in Spain were published the year 2009, adapting the 2005 Euro-
pean guidelines [17, 18]. Yet, this text left numerous decisions regarding disease management
open to interpretation at the healthcare centre level. Posteriorly, diagnosis and treatment
guidelines were updated in Catalonia the year 2011 by the Catalan Society of Neurology,
emphasising the need for multidisciplinary care explicitly to optimise use of resources and
improve life quality and survival [19]. Additionally palliative care and end of life support is
considered extremely relevant in these patients [16, 19]. Herein, data suggested that patient’s
death occurred principally in extended care facilities or at the patients’ residence.
Regarding disease comorbidities, the system indicated a high proportion of patients with
various chronic conditions affecting more than 4 systems (83.24%), presumably corresponding
to a great variety of syndromes. This proportion was 3.54 times higher than in the general pop-
ulation, which was 23.5% the same year [20]. Moreover, the Catalan Institute of Health has
measured a correlation between the presence of multiple chronic conditions and disease com-
plexity, which is associated with a more intensive use of healthcare [9]. Some of these condi-
tions might correspond to the most frequent secondary diagnoses that included hypertension,
type II diabetes, hypercholesterolemia, disorders of lipoid metabolism and breathing difficul-
ties likely to be directly derived from ALS. A previous study linked ALS with several preceding
diseases as asthma or diabetes [21], although herein comorbidities cannot be interpreted as
precedent diseases. Respiratory difficulties were presumably a consequence of ALS, being a
common reason for admission in these patients [22, 23]. Additionally, patients’ old age cannot
be ruled out as the cause for this prevalence of chronic diseases. In addition, the database
reflects a number of patients at a certain level of risk that doubles that in the general population
[9]. These parameters are likely to impact disease burden, increasing medical expenses.
On the other hand, direct medical costs per patient averaged €1,168 per year. Previous esti-
mations in Spain measured a cost per patient of around €1,247 when only hospital admissions,
procedures, emergencies and outpatient care were considered [5].
The progressive neurodegenerative nature of ALS determines a more intensive use of
healthcare resources. In earlier estimations, when direct medical costs were added to at-home
care, follow-up medication, rehabilitation, orthopaedic devices and transportation the sum
reached €8,892 per patient [5]. These elements should be included in prospective studies to
provide a wider picture of ALS burden. Herein, the database only allowed calculating costs
directly derived from admissions, which limited the impact of this study. This factor must be
taken into account in prospective resource allocation evaluations. Another limitation was the
Table 4. Direct medical costs associated to patients’ use of healthcare resources (2007–2017) based on mean costs established by the regional government.
Admissions Total cost
Scheduled Cost Urgent Cost
Primary care 50,842 22,355 €41 26,230 €62 €2,542,815
Mean days of stay Cost per day Cost per admission
Hospitals Inpatient 2,319 6.6 €310 €2,046 €4,744,674
Cost per admission
Hospitals Outpatient 384 €104 €39,936
Cost per admission
Extended care 1387 €67 €93,525
Cost per admission
ER 3836 €130 €498,680
Total €7,919,630
https://doi.org/10.1371/journal.pone.0223772.t004
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incompleteness of data due to the database characteristics. Additionally, missing data ham-
pered more consistent analyses.
Conclusions
The 58,775 admission records analysed revealed the importance of primary healthcare for ALS
patients while, hospitalisation costs remain determinant in the calculation of the total burden
ALS supposes for healthcare systems. The high proportion of patients with chronic conditions
affecting more than 4 organ systems should be taken into account for further research in order
to adapt and improve treatment protocols.
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